9.49
+8.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Candel Therapeutics
From its filings with the US Securities and Exchange Commission
Candel Therapeutics is based in Needham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CADL. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2022, it reported revenue of $125,000.
We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. This is intended to lead to in-situ immunization against the injected tumor and uninjected distant metastases. Local administration is designed to achieve these therapeutic effects while minimizing systemic exposure and associated toxicity.
The immune cells induced by these viral immunotherapies are believed to target patients’ specific tumor antigens, potentially improving responses in immunologically “hot” tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed “cold” tumors with limited immune response into “hot” tumors. While our product candidates are administered directly into the tumor, we have observed systemic immune responses in our preclinical studies and clinical trials that may indicate the potential of our product candidates to induce systemic immune response against distal, uninjected tumors, also known as an “abscopal” effect.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Jul 2021
- Employees
- 55
- Website
- candeltx.com ↗
- Head office
- 117 KENDRICK STREET, NEEDHAM, MA, 02494
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Paul ManningChairman of the Board
- Dr. Paul TakPresident, Chief Executive Officer, Director, since 2020
- Dr. Estuardo Aguilar- CordovaCo-Founder, Chief Scientific Officer, Director, since 2020
- Mr. John CanepaChief Financial Officer, since 2020
- Dr. Laura AguilarChief Medical Officer, since 2014
- Mr. Luis AguilarExecutive Director Programs
- Mr. Daniel GirouxVice President - Manufacturing
- Ms. Andrea ManzaneraSenior Director - Clinical Research, since 2011
- Mr. Stephen RocamboliChief Business Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 43
- Social
- 43
- Governance
- 34
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Late clinical stage biotechnology company with two clinical-stage viral immunotherapy platforms.
- Candel Therapeutics has two product candidates: CAN-2409 and CAN-3110 for cancer treatment.
- The enLIGHTEN Discovery Platform uses human biology and advanced analytics for solid tumor therapies.
Weaknesses
- Headquartered in Needham, Massachusetts with 55 employees as of the latest data.
- The company went public on 27 July 2021 with a focus on late-stage development.
- Candel Therapeutics employs 76 full-time employees in the Health Care sector.
Opportunities
- The Health Care sector shows growth potential for viral immunotherapies in cancer treatment.
- Candel Therapeutics' platforms could expand into new solid tumor markets.
- The biotechnology industry in the US offers opportunities for clinical-stage companies.
Threats
- The biotechnology sector faces intense competition from established pharmaceutical companies.
- Regulatory challenges may delay the approval of viral immunotherapies.
- Candel Therapeutics' reliance on two product candidates poses a risk if clinical trials fail.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.